Paris-based biotech startup SporeBio has successfully raised $23 million in a Series A funding round to enhance microbiology testing. The company aims to revolutionize pathogen detection by utilizing artificial intelligence to reduce testing times from days to mere minutes. This innovative approach is expected to significantly improve efficiency and safety in microbiological testing, addressing urgent needs in the field. The funding will support the development and deployment of their AI-powered technology, positioning SporeBio as a key player in the intersection of technology and biotechnology.